Pfizer Receives “Approvable” Letter For MRSA Antibiotic Dalbavancin
This article was originally published in The Pink Sheet Daily
Executive Summary
Broad range of issues - from trial design to manufacturing - must be addressed before firm can add product to its antibiotic portfolio.